Abstract: In some embodiments, the present disclosure relates to an integrated circuit (IC) in which a memory structure comprises an inhibition layer inserted between two ferroelectric layers to create a tetragonal-phase dominant ferroelectric structure. In some embodiments, the ferroelectric structure includes a first ferroelectric layer, a second ferroelectric layer overlying the first ferroelectric layer, and a first inhibition layer disposed between the first and second ferroelectric layers and bordering the second ferroelectric layer. The first inhibition layer is a different material than the first and second ferroelectric layers.

Abstract: A two-stage oil-injected screw air compressor includes an integrated compression casing, and the integrated compression casing further includes a first stage compression chamber, an intermediate cooling channel, and a second stage compression chamber parallel stacked in the integrated compression casing. A straightforward oil injector aims at the intermediate cooling channel to spray lubricating oil into the intermediate cooling channel.

Abstract: A two-stage oil-injected screw air compressor includes an integrated compression casing, and the integrated compression casing further includes a first stage compression chamber, an intermediate cooling channel, and a second stage compression chamber parallel stacked in the integrated compression casing. A straightforward oil injector aims at the intermediate cooling channel to spray lubricating oil into the intermediate cooling channel.

Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.

Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.